Table 5 Post-surgical malignancy rate of FNAB and FNAB with BRAFV600E genetic testing in different cytology Bethesda groups.
Bethesda groups | FNAB alone | FNAB with BRAFV600E genetic testing | p | ||||
|---|---|---|---|---|---|---|---|
Number of surgical nodules | Number of malignant nodules | Malignancy rate | Number of surgical nodules | Number of malignant nodules | Malignancy rate | ||
I | 16 | 8 | 50.00% | 12 | 9 | 75.00% | 0.253 |
II | 68 | 19 | 27.94% | 17 | 6 | 35.29% | 0.563 |
III | 63 | 32 | 50.79% | 85 | 78 | 91.76% | < 0.001 |
IV | 33 | 9 | 27.27% | 10 | 1 | 10.00% | 0.407 |
V | 194 | 175 | 90.21% | 152 | 150 | 98.68% | 0.001 |
VI | 1691 | 1680 | 99.35% | 1729 | 1725 | 99.77% | 0.073 |
Total | 2065 | 1923 | 93.12% | 2005 | 1969 | 98.20% | < 0.001 |
